News
A post-hoc analysis of STRIDE confirms the benefit of GLP-1 RA in patients with peripheral arterial disease and type 2 ...
Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...
Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including improvement in symptoms, quality of life ...
At week 52, the estimated median ratio to baseline in maximum walking distance was 1.21 in the semaglutide group compared to 1.08 in the placebo group.
CHICAGO — Semaglutide 1 mg improves walking distance in patients with early peripheral artery disease and type 2 diabetes, regardless of baseline diabetes duration, HbA1c, BMI and concomitant ...
Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including improvement in symptoms, quality of life, and ...
Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including improvement in symptoms, quality of life, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results